Preclinical models evaluating the effects of agonist and antagonist ligands that modulate Sig-1R activity have allowed us to widely understand their contribution to cytoprotective, reparative, and anti-inflammatory mechanisms, as well as the promise that their use projects for interventions in cardiovascular and renal diseases [16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33]. Here, SIGMAR1 is linked to kidney disorder.